European Medicines Agency (EMA)

Agence européenne des médicaments

Search Open Yearbook

This information is part of the Open Yearbook, a free service of UIA's subscription-based Yearbook of International Organizations (YBIO). It includes profiles of non-profit organizations working worldwide in all fields of activity. The information contained in the profiles and search functionality of this free service are limited.

The full-featured Yearbook of International Organizations (YBIO) includes over 70,000 organization profiles, additional information in the profiles, sophisticated search functionality and data export. For more information about YBIO, please click here or contact us.

The UIA is a leading provider of information about international non-profit organizations. The aim of the Open Yearbook is to promote the activities of international non-governmental organizations (INGOs) and intergovernmental organizations (IGOs).

Contact Details

Available with paid subscription only.


Established 22 July 1993, by Council of the European Union Regulation (EEC) No 2309/93. Original title: European Agency for the Evaluation of Medicinal Products (EMEA) -- Agence européenne pour l'évaluation des médicaments. Became operational, Feb 1995, London (UK). Current name adopted 2004. A decentralized agency of European Union (EU).


Protect and promote public and animal health through evaluation and supervision of medicines for human and veterinary use; support medicines development by giving scientific advice and providing guidance to developers of medicines; carry out robust scientific evaluations of medicines for human and veterinary use that are the basis of the European Commission's decision on whether a medicine can be authorized for marketing throughout the EU; monitor the safety of medicines in the EU after they have been authorized; provide information on medicines to healthcare professionals and patients.

Available with paid subscription only.


Responsible for the centralized procedure for the authorization of medicines, where there is a single application, a single evaluation and a single authorization throughout the EU. The centralized procedure is compulsory for certain medicines, including human medicines intended for the treatment of HIV/AIDS, cancer, diabetes or neurodegenerative diseases, designated orphan medicines intended for the treatment of rare diseases, and medicines derived from genes, cells, tissue-engineering and biotechnology processes. It also applies to all veterinary medicines intended for use as performance enhancers in order to promote growth of animals or to increase yields from animals. Coordinates the work of about 4,500 experts from EU Member States. These experts carry out evaluation of medicines throughout their life-span and are members of the Agency's scientific committees, working parties and groups.


Available with paid subscription only.


Available with paid subscription only.


Available with paid subscription only.


Available with paid subscription only.

Relations with Inter-Governmental Organizations

Relations with 10 inter-governmental organizations.
More detailed data available with paid subscription.

Relations with Non-Governmental Organizations

Relations with 3 non-governmental organizations.
More detailed data available with paid subscription.


Available with paid subscription only.


Members in 31 countries
More detailed data available with paid subscription.

Type I Classification

Available with paid subscription only.

Type II Classification

Available with paid subscription only.

Subjects *

  • Social Activity
    • Agency
  • Health Care
    • Health
    • Pharmacy
    • Veterinary

UN Sustainable Development Goals **

GOAL 3: Good Health and Well-being



Last News Received

9. Jul 2018
* Subject classification is derived from the organization names and aims.
** UN SDGs are linked to the subject classification.

You are viewing an organization profile from the Yearbook of International Organizations Online.
← return to your search page to find additional profiles.
Terms of Use

UIA allows users to access and make use of the information contained in its Databases for the user’s internal use and evaluation purposes only. A user may not re-package, compile, re-distribute or re-use any or all of the UIA Databases or the data* contained therein without prior permission from the UIA.

Data from database resources may not be extracted or downloaded in bulk using automated scripts or other external software tools not provided within the database resources themselves. If your research project or use of a database resource will involve the extraction of large amounts of text or data from a database resource, please contact us for a customized solution.

UIA reserves the right to block access for abusive use of the Database.

* Data shall mean any data and information available in the Database including but not limited to: raw data, numbers, images, names and contact information, logos, text, keywords, and links.